JP Morgan Maintains Overweight on ResMed, Raises Price Target to $195
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst David Low has maintained an Overweight rating on ResMed (NYSE:RMD) and increased the price target from $160 to $195.
January 09, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst David Low reaffirmed an Overweight rating on ResMed and raised the price target to $195, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like David Low from JP Morgan is a strong positive signal for ResMed. It suggests that the analyst has confidence in the company's future performance and growth potential. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100